AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17135039
Drug: Cyclical hormone
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclical hormone replacement therapy (HRT) with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for 1 year
Trial: 17135039
Drug: 17beta-estradiol gel
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol gel with the same schedule of MPA administration for 1 year
Trial: 9219145
Drug: Drug use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug use before or during sex
Trial: 6198057
Drug: Prioderm lotion
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prioderm lotion (0.5% malathion in isopropanol)
Trial: 23792399
Drug: Single-visit root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-visit root canal treatment
Trial: 18368947
Drug: Procaterol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol (20 µg, inhaled three times a day)
Trial: 18368947
Drug: Oxitropium bromide
RxNorm normalized name: oxitropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxitropium bromide (200 µg, inhaled three times a day)
Trial: 17165499
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with Chinese medicine
Trial: 11766711
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine
Trial: 11100349
Drug: Cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 5 mg% (Group A2)
Trial: 11100349
Drug: Cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 10 mg% (Group B2)
Trial: 11100349
Drug: Cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic total parenteral nutrition (TPN) when total bilirubin > 20 mg% (Group C2)
Trial: 11100349
Drug: Non-cyclic total
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-cyclic total parenteral nutrition (TPN)
Trial: 8383933
Drug: Doxacurium (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxacurium (0.05 mg/kg)
Trial: 8383933
Drug: Pancuronium (0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.14 mg/kg)
Trial: 8383933
Drug: Pipecuronium (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium (0.10 mg/kg)
Trial: 31615775
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of testosterone cream daily for 10 weeks
Trial: 28984843
Drug: Weekly family
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly family psychosocial intervention
Trial: 22648466
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg · kg‐1)
Trial: 20921123
Drug: Acamprosate (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (initial oral loading followed by 1998 mg daily)
Trial: 9372653
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (975 mg)
Trial: 3501540
Drug: FUra plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra plus leucovorin (200 mg/m2 daily for 5 days)
Trial: 3501540
Drug: FUra plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra plus leucovorin (20 mg/m2 daily for 5 days)
Trial: 30365408
Drug: 2.5% topical
RxNorm normalized name: BP 2.5% Topical Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% topical ketoprofen gel
Trial: 21562038
Drug: Intravenous methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous methotrexate (IV MTX) during interim maintenance phases
Trial: 21562038
Drug: Oral methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate (PO MTX) during interim maintenance phases
Trial: 19433681
Drug: Modified high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified high-dose induction phase (arm A): 4 weeks of 10 MU/m² IFN-alpha-2b IV for 2 weeks and 10 MU/m² IFN-alpha-2b SC for 2 weeks followed by 23 months of low-dose IFN-alpha-2b 3 MU SC three times a week
Trial: 19433681
Drug: Low-dose IFN-alpha-2b
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IFN-alpha-2b only (arm B): 3 MU three times a week for 24 months
Trial: 10990220
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg tablet once daily for 13 days)
Trial: 3539163
Drug: Epoprostenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol infusion
Trial: 16148284
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg once daily for seven days)
Trial: 9631752
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) administered every 4 weeks, with NSAIDs initially maintained.
Trial: 2969002
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone (100 micrograms/kg)
Trial: 2969002
Drug: Daily and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily and alternate day prednisone treatments
Trial: 25740262
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) single oral doses of 1/10/50/100/200 mg
Trial: 25740262
Drug: Asunaprevir (ASV)
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir (ASV) single oral doses of 200/400/600/900/1200 mg
Trial: 25740262
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (DCV) multiple oral doses of 1/10/100 mg once-daily for 14 days
Trial: 25740262
Drug: Asunaprevir (ASV)
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir (ASV) multiple oral doses of 200/400/600 mg every 12 hours for 14 days
Trial: 15303633
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once daily for 7 days
Trial: 1641600
Drug: erythromycin stearate
RxNorm normalized name: Erythromycin Stearate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythromycin stearate 500 mg b.i.d.
Trial: 20710083
Drug: Cervical manipulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical manipulation (specific dosage and duration not provided)
Trial: 17981886
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between IV-S and IV-G
Trial: 17130263
Drug: Olmesartan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (40 mg) for 16 weeks
Trial: 11552355
Drug: McKenzie-concept, mobilisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: McKenzie-concept, mobilisation therapies, traction
Trial: 11552355
Drug: Pain reducing
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain reducing physical therapies (cold or electrotherapy)
Trial: 11552355
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs, analgesics, muscle relaxants
Trial: 9382981
Drug: Interferon‐α therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐α therapy
Trial: 8037993
Drug: Nitrates (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (40 mg isosorbide dinitrate twice daily)
Trial: 31281988
Drug: ONO-4474 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO-4474 (100 mg, orally, twice daily for 28 days)
Trial: 24693945
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration exercise twice a week for 3 months
Trial: 24693945
Drug: General exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General exercise twice a week for 3 months
Trial: 20632193
Drug: lafutidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine (20 mg/day)
Trial: 20632193
Drug: famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: famotidine (40 mg/day)
Trial: 17554249
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg/day elemental zinc in multivitamin syrup for 2 weeks)
Trial: 17554249
Drug: Multivitamin syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin syrup without zinc (control)
Trial: 2276389
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg once daily
Trial: 2276389
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg b.d.
Trial: 26475246
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid bolus administration guided by noninvasive cardiac output monitor after passive leg-raising maneuver
Trial: 23141856
Drug: High-intensification intravenous
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensification intravenous diuretic therapy
Trial: 23141856
Drug: Low-intensification intravenous
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensification intravenous diuretic therapy
Trial: 20415693
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose combination (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Trial: 20415693
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose combination (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Trial: 20415693
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose metformin (metformin 1000 mg b.i.d.)
Trial: 20415693
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose metformin (metformin 500 mg b.i.d.)
Trial: 20415693
Drug: Sitagliptin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin monotherapy (sitagliptin 100 mg q.d.)
Trial: 20415693
Drug: Placebo/metformin (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/metformin (switched to metformin monotherapy uptitrated to 1000 mg b.i.d.)
Trial: 17086017
Drug: Hydrolyzed whey
RxNorm normalized name: amino acids/hydrolyzed collagen/hydrolyzed whey 15 gram-100 kcal/30 mL ORAL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrolyzed whey protein (20 g/d)
Trial: 17086017
Drug: Unmodified whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmodified whey protein (control treatment)
Trial: 10486435
Drug: Film-coated tablet
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablet formulation of risedronate
Trial: 10486435
Drug: Gelatin capsule
RxNorm normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsule formulation of risedronate
Trial: 6374946
Drug: Tube gastrostomy
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tube gastrostomy (Group G)
Trial: 30351426
Drug: Personalized antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antibiotic strategies (COMPASS)
Trial: 26846336
Drug: Methods designed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methods designed to enhance self-efficacy (treatment)
Trial: 25231491
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 or 1 mg/kg)
Trial: 17631326
Drug: Intravesical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical therapy (control for group 2)
Trial: 7817931
Drug: Sotalol (alternate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (alternate therapy group)
Trial: 2266432
Drug: Cross-covering senior
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-covering senior resident (CC group)
Trial: 543911
Drug: mezlocillin (Baypen)
RxNorm normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mezlocillin (Baypen) at a daily dosage of 2 x 5 g or 3 x 5 g
Trial: 28397833
Drug: Short-term oral
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term oral immunotherapy (OIT) with Cry j 1-galactomannan conjugate
Trial: 26952142
Drug: Standardized extract
RxNorm normalized name: Spring Valley Olive Leaf Standardized Extract 150mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized extract of Prunus mume (150 mg)
Trial: 21940716
Drug: Paricalcitol (injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol (injection and capsules)
Trial: 18198986
Drug: Fenofibrate treatment
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate treatment for 3 months
Trial: 15188947
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg U/day of Ultrasome-CoQ10 for 3 months
Trial: 11151290
Drug: Diet only
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet only treatment group
Trial: 9343478
Drug: Differentiated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differentiated treatment based on clinical sleep disturbances (including amitriptylin, imipramine, diazepam, nootropic drugs)
Trial: 3537823
Drug: Naftidrofuryl treatment
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl treatment
Trial: 31464623
Drug: Treatment effect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effect at endline
Trial: 31464623
Drug: Baseline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment effect
Trial: 25588410
Drug: Midwife oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midwife oral assessment and referral to private/public/health fund dental services pathway (Intervention Group 1)
Trial: 25588410
Drug: Midwife oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midwife oral assessment and referral to local free public dental services pathway (Intervention Group 2)
Trial: 25588410
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health promotional material only (Control Group)
Trial: 21672049
Drug: 20 ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ng/ml tacrolimus
Trial: 16501756
Drug: Cognitive-behavioral approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral approach without nicotine replacement therapy (GB)
Trial: 16501756
Drug: Cognitive-behavioral approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral approach with nicotine replacement therapy (GBA)
Trial: 10695262
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training (attending classes at least twice a week for 25 weeks, each lasting two hours)
Trial: 10695262
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (attending recreational classes twice a month)
Trial: 9359554
Drug: Cardioselective beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta blockers
Trial: 8096545
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dose of ebastine syrup
Trial: 8096545
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dose of ebastine syrup
Trial: 3805797
Drug: Regimen II
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen II (Dapsone, rifampicin, and clofazimine 100 mg on alternate days)
Trial: 28641216
Drug: PEGASUS (8-session
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGASUS (8-session treatment)
Trial: 24351088
Drug: Active waiting
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active waiting list control group with delayed treatment
Trial: 20514964
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 1 microg/kg (group C1, n=39)
Trial: 20514964
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine 2 microg/kg (group C2, n=41)
Trial: 16623401
Drug: Minimal low-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal low-flow anesthesia (LFA) at 0.3 mL/min
Trial: 16623401
Drug: Semi-closed high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-closed high flow anesthesia (HFA) at 2 L/min
Trial: 14763696
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg bolus IV, followed by 1 mg/kg/hour continuous infusion for 10 hours)
Trial: 14763696
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL saline IV)
Trial: 7871655
Drug: Pikamilon administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pikamilon administration
Trial: 2893187
Drug: Zidovudine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (250 mg 6‐hourly, 500 mg 6‐hourly, or 500 mg 12‐hourly)
Trial: 6145726
Drug: Alprazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (2 mg)
Trial: 30286443
Drug: Dronabinol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (10 mg and 30 mg)
Trial: 30286443
Drug: CBD (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (750 mg)
Trial: 30286443
Drug: CBD (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (1500 mg)
Trial: 30286443
Drug: CBD (4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (4500 mg)
Trial: 30286443
Drug: CBD (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (1500 mg and 4500 mg)
Trial: 21541241
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy with gemcitabine (1250 mg/m² on days 1 and 4), cisplatin (75 mg/m² on day 2), and erlotinib (150 mg daily on days 5-15, followed by maintenance erlotinib)
Trial: 21541241
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy with gemcitabine, cisplatin, and erlotinib
Trial: 19541016
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (0.067 g kg(‐1) h(‐1))
Trial: 17944739
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (botox and saline)
Trial: 2086423
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia (RBA) with 5 ml of bupivacaine/lidocaine mixture with adrenaline
Trial: 678373
Drug: Existing practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing practice of non-depolarizing neuromuscular blocking drugs
Trial: 31246882
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Trial: 29761313
Drug: Yisui Shengxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yisui Shengxue Granules (12 g/bag three times a day) for 3 months
Trial: 27456034
Drug: sarpogrelate in
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sarpogrelate in addition to aspirin